Literature DB >> 16671089

The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.

Yan Wu1, Andrea T Hooper, Zhaojing Zhong, Larry Witte, Peter Bohlen, Shahin Rafii, Daniel J Hicklin.   

Abstract

Vascular endothelial growth factor receptor 1 (VEGFR-1) is present on endothelial cells and subsets of human tumor cells, raising the hypothesis that angiogenic factors may promote tumor growth both by inducing angiogenesis and directly signaling through activation of VEGFR-1 on tumor cells. Here, we report that VEGFR-1 is expressed on a panel of 16 human breast tumor cell lines, and the vasculature and the tumor cell compartment of a subset of breast carcinoma lesions, and that selective signaling through VEGFR-1 on breast cancer cells supports tumor growth through downstream activation of the p44/42 mitogen-activated protein kinase (MAPK) or Akt pathways. Ligand-stimulated proliferation of breast tumor cells was inhibited by specific blockade with an anti-VEGFR-1 neutralizing monoclonal antibody. Treatment with anti-VEGFR-1 mAb significantly suppressed the growth of DU4475, MCF-7, BT-474 and MDA-MB-231 breast xenografts in athymic mice. Histological examination of anti-VEGFR-1 mAb treated tumor xenografts showed a significant reduction of activation of the p44/42 MAPK or Akt pathways in tumor cells resulting in an increase in tumor cell apoptosis. Importantly, cotreatment with mAbs targeting human VEGFR-1 on tumor cells and murine VEGFR-1 on vasculature led to more potent growth inhibition of breast tumor xenografts. The results suggest that VEGF receptors may not only modulate angiogenesis, but also directly influence the growth of VEGF receptor expressing tumors. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16671089     DOI: 10.1002/ijc.21865

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  66 in total

Review 1.  Roles for growth factors in cancer progression.

Authors:  Esther Witsch; Michael Sela; Yosef Yarden
Journal:  Physiology (Bethesda)       Date:  2010-04

2.  Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

Authors:  William M Merritt; Alpa M Nick; Amy R Carroll; Chunhua Lu; Koji Matsuo; Melissa Dumble; Nicholas Jennings; Shuyun Zhang; Yvonne G Lin; Whitney A Spannuth; Aparna A Kamat; Rebecca L Stone; Mian M K Shahzad; Robert L Coleman; Rakesh Kumar; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

3.  Ontogenomic study of the relationship between number of gene splice variants and GO categorization.

Authors:  Ari B Kahn; Barry R Zeeberg; Michael C Ryan; D Curtis Jamison; David M Rockoff; Yves Pommier; John N Weinstein
Journal:  Bioinformatics       Date:  2010-07-08       Impact factor: 6.937

4.  PRH/Hhex controls cell survival through coordinate transcriptional regulation of vascular endothelial growth factor signaling.

Authors:  Peter Noy; Hannah Williams; Anyaporn Sawasdichai; Kevin Gaston; Padma-Sheela Jayaraman
Journal:  Mol Cell Biol       Date:  2010-02-22       Impact factor: 4.272

5.  Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth.

Authors:  Christine F O'Neill; Sumithra Urs; Christina Cinelli; Alexis Lincoln; Robert J Nadeau; Ruth León; Jessica Toher; Carla Mouta-Bellum; Robert E Friesel; Lucy Liaw
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

6.  Functional significance of VEGFR-2 on ovarian cancer cells.

Authors:  Whitney A Spannuth; Alpa M Nick; Nicholas B Jennings; Guillermo N Armaiz-Pena; Lingegowda S Mangala; Christopher G Danes; Yvonne G Lin; William M Merritt; Premal H Thaker; Aparna A Kamat; Liz Y Han; James R Tonra; Robert L Coleman; Lee M Ellis; Anil K Sood
Journal:  Int J Cancer       Date:  2009-03-01       Impact factor: 7.396

7.  Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF.

Authors:  Meng Tong; Brandon Lloyd; Ping Pei; Susan R Mallery
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

8.  VEGFR-1 Pseudogene Expression and Regulatory Function in Human Colorectal Cancer Cells.

Authors:  Xiangcang Ye; Fan Fan; Rajat Bhattacharya; Seth Bellister; Delphine R Boulbes; Rui Wang; Ling Xia; Cristina Ivan; Xiaofeng Zheng; George A Calin; Jing Wang; Xiongbin Lu; Lee M Ellis
Journal:  Mol Cancer Res       Date:  2015-06-03       Impact factor: 5.852

9.  Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy.

Authors:  Jenny Yao; Xiumin Wu; Guanglei Zhuang; Ian M Kasman; Tobias Vogt; Vernon Phan; Masabumi Shibuya; Napoleone Ferrara; Carlos Bais
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

10.  Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors.

Authors:  Zhican Qu; Sabrina Van Ginkel; Anshu M Roy; Louise Westbrook; Mubina Nasrin; Yulia Maxuitenko; Andra R Frost; Delicia Carey; Wenquan Wang; Rongbao Li; William E Grizzle; Jaideep V Thottassery; Francis G Kern
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.